Hypoxia-inducible factor 1 (HIF-1) is a key regulator of O 2 homeostasis, which regulates the expression of several genes linked to angiogenesis and energy metabolism. Tumor hypoxia has been shown to be associated with poor prognosis in a variety of tumors, and HIF-1 induced by hypoxia plays pivotal roles in tumor progression. The presence of putative HIF-1-binding sites on the promoter of human telomerase reverse transcriptase gene (hTERT) prompted us to examine the involvement of HIF-1 in the regulation of hTERT and telomerase in tumor hypoxia. The telomeric repeat amplification protocol (TRAP) assay revealed that hypoxia activated telomerase in cervical cancer ME180 cells, with peak induction at 24-48 h of hypoxia. Notably, hTERT mRNA expression was upregulated at 6-12 h of hypoxia, concordant with the elevation of HIF-1 protein levels at 6 h. hTERT protein levels were subsequently upregulated at 24 h and later. Luciferase assays using reporter plasmids containing hTERT core promoter revealed that hTERT transcription was significantly activated in hypoxia and by HIF-1 overexpression, and that the two putative binding sites within the core promoter are responsible for this activation. Chromatin immunoprecipitation assay identified the specific binding of HIF-1 to these sites (competing with c-Myc), which was enhanced in hypoxia. The present findings suggest that hypoxia activates telomerase via transcriptional activation of hTERT, and that HIF-1 plays a critical role as a transcription factor. They also suggest the existence of novel mechanisms of telomerase activation in cancers, and have implications for the molecular basis of hypoxia-induced tumor progression and HIF-1-based cancer gene therapy.
Introduction
During tumor development, cells are exposed to a hypoxic environment, because the proliferating malignant cells outstrip the local supply of oxygen and nutrients after tumors attain steady-state volume. To resume further growth, tumor cells must adapt to hypoxic stress through alterations in cellular metabolism and stimulation of neovascularization, which provides the additional blood needed to sustain cellular proliferation. These adaptive responses provide tumor cells with the capacity to grow continuously and increase tumor size, and thereby confer selective growth advantage, resulting in the generation of more aggressive phenotypes. Consistent with this concept is the finding that tumor hypoxia has been associated with poor outcome in a number of human malignancies (Birner et al., 2000; Schindl et al., 2002; Sivridis et al., 2002) .
A key regulator of the cellular response to oxygen deprivation is the transcription factor hypoxia-inducible factor 1 (HIF-1) (Semenza, 1999) . HIF-1 is a heterodimeric complex composed of the two basic helix-loophelix PAS domain (bHLH-PAS) subunits HIF-1a and HIF-1b (Wang et al., 1995) . Whereas HIF-1b (also known as aryl hydrocarbon receptor nuclear translocator) is constitutively expressed, the expression of HIF-1a is tightly coupled to the ambient oxygen tension (Jiang et al., 1996) . Under normoxic conditions, the HIF-1a gene is constitutively transcribed; however, the HIF-1a protein is expressed at very low levels due to rapid degradation via the ubiquitin-proteasome pathway. Thus, HIF-1a protein expression is key to determining HIF-1 activity in hypoxia. Over 40 HIF-1 target genes have been identified, most of which encode proteins that regulate oxygen homeostasis and are critical for developmental and physiological processes in hypoxic environments (Semenza, 2000) .
One important factor required for indefinite tumor growth is the activation of telomerase, which confers immortality to cells via restoration of telomeres. Hypoxic stress is known to induce genetic instability by accelerating DNA breakage and gene amplification in tumor cells (Russo et al., 1995; Coquelle et al., 1998) . While such genome rearrangement may trigger more aggressive phenotypes, it may also cause lethal genetic damage in the presence of an intact DNA damage checkpoint Greenberg et al., 1999) . These findings suggest the existence of mechanisms by which tumor cells can protect their chromosome structure from hypoxia-induced genotoxicity. Consistent with this concept, previous studies have demonstrated that telomerase is activated under hypoxic conditions (Seimiya et al., 1999; Minamino et al., 2001) , suggesting that telomerase activation is a mechanism that protects against genetic stress induced by hypoxia. However, the molecular mechanisms by which hypoxia activates telomerase are not fully understood.
Interestingly, computer-assisted homology searches have revealed potential binding sites for HIF-1 on the gene promoter of human telomerase reverse transcriptase (hTERT), a catalytic subunit of telomerase. Based on these observations, we hypothesized that HIF-1 is involved in the regulation of hTERT and telomerase. In the present study, we examined the effect of hypoxia on telomerase activity in cervical cancer cells, and identified a novel mechanism of hypoxia-induced telomerase activation via HIF-1. Notably, HIF-1 binds to the core promoter of hTERT and acts as a potent transactivator.
Results
We first examined the effect of hypoxia on telomerase activity in cervical cancer ME180 cells. Cells were cultured in hypoxia (1% O 2 ) or normoxia (20% O 2 ) for 24 and 48 h, and cell pellets were analysed using TRAP assays. As shown in Figure 1a and b, significant induction of telomerase activity was induced by hypoxic exposure. Short-term exposure (p12 h) was insufficient to induce telomerase activity. The levels of induction peaked at 24-48 h, with graduate decrease at 72 h (data not shown). Since transcriptional regulation of hTERT is the major mechanism of telomerase activation, we next examined the effect of hypoxia on hTERT mRNA expression. After ME180 cells were cultured in hypoxia for different durations, cell pellets were recovered for RNA extraction, and hTERT mRNA expression was semiquantified by RT-PCR (Figure 1c) . A marked increase in hTERT mRNA expression was observed at 6 h, with peak induction at 12 h. The hTERT protein levels were then examined by Western blotting using specific anti-hTERT antibody (Figure 1d ). Hypoxic exposure for 12 h had no effect on hTERT protein levels, whereas exposure for 24 h induced a significant increase in hTERT protein levels. Activation of hTERT mRNA expression at 6-12 h with subsequent increase in hTERT protein levels and telomerase activity at 24 h is consistent with the presence of a direct pathway for telomerase activation by hypoxia via transcriptional upregulation of the hTERT gene.
We then investigated the involvement of HIF-1 in telomerase activation in hypoxia. To examine whether HIF-1 expression was upregulated in ME180 cells in hypoxia, Western blot analysis was performed. ME180 cells were cultured in hypoxia or normoxia for 6-24 h, and nuclear extracts were analysed. As expected, HIF-1a expression was markedly upregulated at 6 h after hypoxic stimulation, compared to normoxic conditions ( Figure 2a) ; this upregulation continued beyond 24 h. We further examined whether HIF-1a is overexpressed in cervical cancer in vivo. Immunohistochemistry revealed that eight of the nine (89%) cervical The activity was quantified in three independent assays and represented as relative telomerase activity. Telomerase was significantly activated at 24 h after hypoxic stimuli, and activation continued beyond 48 h. IC: internal control to normalize the efficiency of PCR amplification. Error bars, 7s.d. (c) RT-PCR assay of changes in hTERT mRNA expression in ME 180 cells incubated in normoxia (N) or hypoxia (H) for different durations. hTERT mRNA expression was upregulated at 6-36 h after hypoxic stimuli. (d) Western blot analysis of levels of hTERT protein expression in ME 180 cells incubated in normoxia (N) or hypoxia (H) for 12 or 24 h. Levels of hTERT protein were markedly upregulated at 24 h after hypoxic stimuli HIF-1 activates telomerase N Yatabe et al cancer samples exhibited significant expression of HIF1a in both nuclei and cytoplasm of tumor cells, and the remaining case exhibited weak expression; the surrounding stroma tissues did not exhibit significant HIF-1a expression (Figure 2b ). Although staining intensity varied among samples, distribution of staining was relatively homogeneous in cancer foci, with no significant heterogeneity between central and margin portions. Normal cervical epithelia were basically negative for significant HIF-1a expression, with only weak or faint expression in parabasal layers of stratified epithelia. Details of these staining patterns are shown in Table 1 . These findings suggest that significant HIF-1a overexpression is common in cervical cancer cells.
HIF-1a is a transcriptional activator of various hypoxia-inducible genes. In a previous study, we cloned a 3.3-kb 5 0 -flanking sequence of the hTERT gene, and identified the proximal 181-bp region as a core promoter responsible for cancer-specific telomerase activation (Takakura et al., 1999) . Computer-assisted sequence analysis revealed the presence of two HIF-1 consensusbinding sequences (5 0 -ACGTG-3 0 ) within the proximal core promoter (Figure 3a ). Transient expression assay was then performed to examine whether hTERT promoter is activated by hypoxia or overexpression of HIF-1a. ME180 cells were transfected with luciferase reporter plasmid containing a core promoter of hTERT (pGL3-181) together with HIF-1a expression vectors or blank vectors and incubated in normoxia or hypoxia for 48 h. Cells were then harvested and luciferase assays were performed. In the absence of HIF-1 overexpression, transcriptional activity of hTERT in hypoxia was approximately twice that of normoxia. When HIF-1 was overexpressed, transcriptional activity of hTERT was twice the level obtained without HIF-1 overexpression in normoxia, and was three times as great in hypoxia ( Figure 3b ). To verify the sequence specificity of this transactivation, we tested mutant reporter plasmids in which two putative HIF1-binding sites were substitution-mutated. As expected, these mutations completely abolished the transcriptional activation by hypoxia and HIF-1a overexpression, suggesting that these sites function as HIF-1a-responsive elements. To further verify the roles of endogeneous HIF-1 in hypoxiainduced hTERT transactivation, RNA interference assays were performed. An siRNA HIF-1a that specifically targets HIF-1a mRNA expression for degradation, thus reducing the expression of HIF-1a mRNA and protein, was generated, as previously reported (Krishnamachary et al., 2003) . The inhibitory effect of this siRNA HIF-1a on HIF-1a expression was confirmed by Western blotting (data not shown). As shown in Figure 4 , hypoxia significantly activated hTERT mRNA expression in mocktransfected cells. This activation was mostly abrogated by the treatment with siRNA HIF-1a , but not by the treatment with control siRNA. These results indicate that endogeneous HIF-1 is involved in hypoxia-induced hTERT transactivation. Finally, we investigated HIF-1 binding to hTERT promoter, using chromatin immunoprecipitation (ChIP) analysis. The DNA of ME 180 cells incubated for 24 h was extracted after crosslinking treatment and incubated with specific anti-HIF-1a antibody or with unrelated control antibody (anti-ERa or -hTERT antibody). The HIF-1a/DNA complexes were then immunoprecipitated, and crosslinking was reversed, followed by PCR amplification targeting putative HIF-1a-binding sites or unrelated sites on the hTERT promoter (Figure 5a ). Immunoprecipitants obtained with anti-HIF-1a antibody generated distinct PCR bands when amplified using primer sets flanking putative HIF-1a sites, whereas those obtained with unrelated antibody produced no PCR bands with the same set of primers. Immunoprecipitants obtained with anti-HIF-1a antibody did not generate significant PCR products when amplified using unrelated primers. These findings suggest that HIF-1a specifically binds to the core promoter of hTERT. The two E-boxes on the hTERT core promoter, overlapping with the putative HIF-1a-binding sites (Figure 3a) , are known to bind c-Myc, a critical transcription factor of hTERT. To examine the competition for binding between HIF-1 and c-Myc, we performed ChIP with cells exposed to normoxia or hypoxia, using HIF-1 or cMyc antibody and the primer set flanking both the binding sites ( Figure 5b ). As expected, the amount of PCR products generated from immunoprecipitants obtained with HIF-1 antibody was elevated in hypoxia, compared with normoxia. In contrast, the amount of PCR products generated from immunoprecipitants obtained with c-Myc antibody was significantly decreased in hypoxia. These findings suggest that hypoxia facilitates HIF-1 binding to hTERT promoter, and that HIF-1 competes with c-Myc for binding, especially in hypoxia. ME180 cells were exposed to Oligofectamine reagent in the absence (mock) or presence of 100 nM siRNA HIF-1a or scrambled siRNA (negative control; siRNA control ) for 4 h. Then, cells were incubated in normoxia or in hypoxia for 12 h, followed by RNA extraction and RT-PCR assays. hTERT mRNA expression was significantly elevated in hypoxia (see mock lanes). This elevation was mostly abrogated by the treatment with siRNA HIF-1a , but not by the treatment with siRNA control HIF-1 activates telomerase N Yatabe et al
Discussion
In the present study, we demonstrated HIF-1-mediated activation of telomerase in hypoxia. HIF-1 is a key regulator of the cellular response to oxygen deprivation, and it has recently been demonstrated that HIF-1 is involved in tumor biology. Analysis of isogenic cell lines in nude mouse xenograft assays indicates that loss of HIF-1 activity results in increased tumor latency and decreased vascular density (Jiang et al., 1997; Maxwell et al., 1997; Carmeliet et al., 1998) , whereas overexpression of HIF-1 results in decreased tumor latency and increased vascular density, volume and permeability (Ravi et al., 2000) . Cancer cells with constitutive expression of HIF-1a are more resistant to apoptosis induced by hypoxia than those without constitutive expression of HIF-1a, and transfection of the latter cells with HIF-1a makes them resistant to apoptosis and increases in vivo tumorigenicity (Akakura et al., 2001) . Consistent with these findings are reports of overexpression of HIF-1 in various types of tumors, associated with treatment failure or unfavorable prognosis (Birner et al., 2000; Schindl et al., 2002; Sivridis et al., 2002) . In the present study, immunohistochemistry identified frequent overexpression of HIF-1a (89%) in cervical cancer tissues, as previously reported (Hockel et al., 1993; Birner et al., 2000) . Although weak expression of HIF-1 was observed in the parabasal layers of stratified epithelia of normal cervix, strong staining was specific to cancer regions, suggesting specific roles for HIF-1 in tumor biology. The significance of weak HIF-1a expression in cervical mucosa is unknown, but it is particularly interesting that weak telomerase activity has been demonstrated in parabasal cells of normal cervix (Yasumoto et al., 1996) , consistent with the localization of HIF-1a expression. 0 -sequence number of the primers used for nested PCR in each target region (see Table 2 ). ME180 cells were treated with formaldehyde for crosslinking, and DNA was extracted and immunoprecipitated with anti-HIF-1a, anti-hTERT or antiERa antibody. After reversal of crosslinking, DNA was purified and used as a template for PCR to amplify each target site. The second PCR products were electrophoresed on a 7.0% polyacrylamide gel and visualized by staining with SYBR Gold. Definite PCR bands were observed only when HIF-1a antibody was used to probe products obtained using the primer sets targeting the putative HIF-1 sites (regions 1 and 2). (b) Competition for hTERT promoter binding between HIF-1 and c-Myc in normoxia and hypoxia was examined by ChIP assay using the primer set flanking both binding sites (regions 1 and 2). The results indicate that binding of HIF-1 to hTERT promoter significantly increased in hypoxia (H), compared to normoxia (N). In contrast, binding of c-Myc apparently decreased in hypoxia, compared to normoxia. NS: non-specific band
HIF-1 activates telomerase N Yatabe et al
The mechanisms by which HIF-1 is involved in poor prognosis or resistance to apoptosis are unclear, but known HIF-1 target genes provide a molecular basis by which HIF-1 overexpression may promote the key aspects of tumor progression. Glucose transporters and glycolytic enzymes promote metabolic adaptation to hypoxia: NOS2 and VEGF promote angiogenesis; IGF-2 promotes cell survival and proliferation (reviewed by Semenza, 2000) . We identified HIF-1a as a novel transcription factor of the hTERT promoter. The present luciferase assays demonstrated that hTERT promoter was significantly activated by hypoxia and HIF-1 overexpression. The RNA interference assays revealed that endogeneous HIF-1 plays roles in hypoxiainduced hTERT transactivation. Thus, hTERT gene is a target of HIF-1. Telomerase activation via transactivation of hTERT may also be a mechanism by which HIF-1 overexpression is associated with aggressive phenotypes or poor prognosis of tumors ( Figure 6 ).
HIF-1 consensus-binding sequences (5 0 -ACGTG-3 0 ), overlapping the E-box (CACGTG), appeared to be responsible for hypoxia-induced hTERT transactivation. The present ChIP analysis revealed that binding activity of HIF-1 was significantly upregulated in hypoxia. Nuclear factors binding these E-boxes have been identified, including c-Myc, Max and Mad (Wu et al., 1999; Kyo et al., 2000; Xu et al., 2001) . It is therefore possible that HIF-1 binding is affected by competition with these factors. Recent findings indicate that hypoxia downregulates c-Myc expression or facilitates degradation of c-Myc (Mazure et al., 2002) . The present ChIP results are consistent with these findings. Whereas binding of HIF-1 to hTERT promoter was enhanced in hypoxia, c-Myc binding significantly declined in hypoxia. These findings suggest a competition for hTERT promoter binding between HIF-1 and cMyc, and that, in hypoxia, the promoter is predominantly bound by HIF-1.
Recent reports indicate that telomerase can be activated in hypoxia via mechanisms other than transactivation of hTERT. Seimiya et al. (1999) demonstrated the roles of the MAP kinase signaling pathway in hypoxia-induced telomerase activation in colon and ovarian cancer cells. Upregulation of hTERT mRNA expression was not observed in these cells after hypoxic exposure. Minamino et al. (2001) reported telomerase activation in vascular smooth muscle cells in hypoxia, demonstrating that phosphorylation of hTERT protein was the major mechanism by which hypoxia activated telomerase. Thus, mechanisms of telomerase activation by hypoxia apparently differ among cell types. This is consistent with the fact that HIF-1 overexpression differs greatly among tumor types. Cervical cancers are representative tumors that frequently exhibit high-level HIF-1 expression.
In summary, the present findings support the hypothesis that HIF-1 induced by tumor hypoxia contributes to telomerase activation via upregulation of hTERT, possibly leading to tumor progression in hypoxia. The present results also suggest the possibility of a novel mechanism of telomerase activation in tumors, and provide insight into the adaptive responses of tumor Figure 6 Proposed roles of HIF-1 in tumor progression in hypoxia. HIF-1 induced by tumor hypoxia contributes to tumor progression via increased angiogenesis and metabolic adaptation, and can act as a transcription factor enhancing hTERT mRNA expression, leading to telomerase activation, which may provide cells with a growth advantage, possibly due to restoration of telomeres and genome stabilization, or via resistance to apoptosis HIF-1 activates telomerase N Yatabe et al cells in hypoxic environments. In terms of clinical relevance, these results may also have implications for a molecular basis for novel cancer therapy targeting HIF-1.
Materials and methods

Cell culture
ME180 cells were obtained from the American Type Culture Collection, and were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum in the presence of 5% CO 2 . For hypoxic exposure, cells were cultured at 1% O 2 in a hypoxia chamber (Coy Laboratory Products, Ann Arbor, MI, USA).
TRAP assay
Telomerase activity was measured by TRAP assay using the TRAP-eze Telomerase Detection Kit system according to the manufacturer's protocol (Intergen, Purchase, NY, USA).
RT-PCR
Expression of hTERT mRNA was analysed by semiquantitative RT-PCR. Briefly, total RNA was isolated from the cells using Isogen (Nippon Gene, Tokyo, Japan) according to the manufacturer's protocol, and cDNA was synthesized from 1 mg of RNA using the RNA PCR kit version 2 (TaKaRa, Otsu, Japan) with random primers. Then, 2-ml aliquots of the reverse-transcribed cDNA were subjected to PCR in 50 ml of 1 Â buffer (10 mM Tris-HCl (pH 8.3), 2.5 mM MgCl 2 , 50 mM KCl) containing 1 mM each of dATP, dCTP, dGTP and dTTP, 2.5 U of Taq DNA polymerase (TaKaRa), and 0.2 mM each of specific primers for hTERT mRNA: 5 0 -CGGAA-GAGTGTCTGGAGCAA-3 0 (LT5) and 5 0 -GGATGAAGCG-GAGTCTGGA-3 0 (LT6) (Nakamura et al., 1997) . Each aliquot underwent 28 cycles of denaturation at 941C for 30 s, annealing at 601C for 30 s, and extension at 721C for 90 s. PCR products were electrophoresed in 7% polyacrylamide gel and stained with SYBR Gold (Molecular Probes, Eugene, OR, USA). The efficiency of cDNA synthesis from each sample was estimated by PCR with b-actin-specific primers, as described previously (Nakamura et al., 1997) . For HIF-1a RNA interference, siRNA HIF-1a was generated as previously described (Krishnamachary et al., 2003) . Briefly, the two oligoribonucleotides 5 0 -AGAGGUGGAUAUGUGUGGGdTdT-3 0 and 5 0 -CCCACACAUAUCCACCUCUdTdT-3 0 were synthesized; the 2 0 -deoxyribonucleosides (dTdT) at the 3 0 ends were removed, and the tqo oligoribonucleotides were annealed (Dharmacon Research, Inc. Lafayette, CO, USA). ME180 cells were exposed to Oligofectamine reagent (Invitrogen, Carlsbad, CA, USA) in the absence (mock) or presence of 100 nM siRNA or scrambled siRNA (negative control; siRNAcontrol ) (Ambion, Austin, TX, USA) for 4 h (Elbashir et al., 2001) . Then, cells were incubated in normoxia or hypoxia for 12 h, followed by RNA extraction and RT-PCR assays.
Plasmid construction
The HIF-1a expression vector was a gift from Dr Eric Haung, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA (Huang et al., 1998) . pGL3-181 is an hTERT promoter-luciferase reporter plasmid in which a 181-bp sequence upstream of the transcription start site of hTERT (designated nt þ 1) and a 77-bp sequence (5 0 -untranslated region) downstream of the transcription start site are cloned into pGL3-Basic (Promega) at MluI and BglII sites (Takakura et al., 1999) . Reporter plasmid pGL3-181 HIF-1MT (previously designated pGL3-MycMT1 þ 2 (Kyo et al., 2000) ) contains substitution mutations in the two putative binding sites of HIF-1 at nt À165 and þ 44, which were introduced by PCR-based site-specific mutagenesis.
Luciferase assay ME180 cells incubated in 24-well dishes for 24 h were transfected with 0.4 mg of reporter plasmid and 0.2 mg of effector plasmid, using LipofectAMINE PLUSt (Invitrogen Corp., Carlsbad, CA, USA), according to the manufacturer's protocol. Cells were incubated in normoxia or in hypoxia for 48 h. Thereafter, cells were harvested and cell extracts were prepared. Luciferase assays were performed using the DualLuciferase Reporter Assay System (Promega, Madison, WI, USA), in which Renilla luciferase plasmids were cotransfected as controls to standardize the transcription efficiency. All experiments were performed at least three times for each plasmid, and the relative luciferase activity reported here is the average of the three resultant values.
Immunohistochemistry
Immunohistochemical analysis of HIF-1a was performed using formalin-fixed, paraffin-embedded specimens of cervical cancer tissues. The sections were autoclaved for 10 min in 1 Â Antigen Retrieval Solution (Biogenex, San Ramon, CA, USA), then incubated for 16 h at 41C with an HIF-1a monoclonal antibody (2.6 mg/ml; NB100-105, Novus Biologicals Littleton, CO, USA). Staining reactions were performed using the ABC-elite kit (Vector Laboratories Inc., Burlingame, CA, USA). Stainings were assessed by two independent pathologists. They were considered positive (strong positive
of cells in the regions of interest were stained; otherwise, they were considered negative (À). 
Western blot analysis
ME180 cells were incubated in normoxia or hypoxia for different time periods, and nuclear extracts were then prepared using the method of Schreiber et al. (1989) . First, 20 mg of protein extract was electrophoresed on a 10% SDS-polyacrylamide gel, and was then transferred to polyvinylidine difluoride membranes. Filters were incubated with specific antibodies against HIF-1a (NB100-105E13, Novus Biologicals) or hTERT (KM 2604, Kyowa Hakko Kogyo, Tokyo Japan), followed by reaction with horseradish peroxidaselinked anti-IgG. Immunoreactive bands were visualized using the ECL detection system (Amersham Bioscience, Piscateway, NJ, USA) in accordance with the manufacturer's suggestions.
ChIP assay
ChIP assays were performed using the ChIP Assay Kit (Upstate, Lake Placid, NY, USA) according to the manufacturer's protocol. Briefly, ME180 cells incubated in 10-cm dishes for 24 h were crosslinked by treatment with formaldehyde (final concentration, 1%) for 10 min at room temperature. After washing with PBS, cells were pelleted and resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCI (pH 8.1), 1 mM DTT, 1 mM PMSF). The lysates were then subjected to sonication to reduce the DNA length to between 500 and 1000 bp, diluted with dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCI (pH 8.1), 167 mM NaCl), and pre-cleared by incubating with Salmon Sperm DNA/protein A agarose-50% slurry for 60 min at 41C. The supernatant was incubated with anti-HIF-1a (NB100-105, Novus Biologicals), anti-hTERT (KM 2604, Kyowa Hakko Kogyo), anti-ERa (sc-786X, Santa Cruz Biotechnology) or anti-c-Myc (sc-42X, Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies at 41C overnight. Immunocomplexes were collected with Salmon Sperm DNA/protein A agarose-50% slurry and eluted after extensive washings, and crosslinkage was reversed by heating at 651C, followed by treatment with 40 mg/ml proteinase K at 451C for 60 min. DNA was recovered by phenol-chloroform/ ethanol precipitation, and was used as a template for PCR to amplify the target sites in the hTERT promoter. The target sites and the corresponding primer sequences are shown in Table 2 and Figure 5 . The PCR products were electrophoresed on a 7% polyacrylamide gel and stained with SYBR Gold (Molecular Probes, Eugene, OR, USA).
